Humacyte (HUMAW) Competitors $0.06 0.00 (-1.85%) As of 05/19/2026 03:15 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock HUMAW vs. AIMDW, ALVOW, ARAV, ACABW, and RNAShould you buy Humacyte stock or one of its competitors? MarketBeat compares Humacyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Humacyte include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry. HUMAW vs. AIMDWHUMAW vs. ALVOWHUMAW vs. ARAVHUMAW vs. ACABWHUMAW vs. RNAHow does Humacyte compare to Ainos?Humacyte (NASDAQ:HUMAW) and Ainos (NASDAQ:AIMDW) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends. Does the media refer more to HUMAW or AIMDW? In the previous week, Ainos had 1 more articles in the media than Humacyte. MarketBeat recorded 1 mentions for Ainos and 0 mentions for Humacyte. Humacyte's average media sentiment score of 0.00 equaled Ainos'average media sentiment score. Company Overall Sentiment Humacyte Neutral Ainos Neutral Is HUMAW or AIMDW more profitable? Company Net Margins Return on Equity Return on Assets HumacyteN/A N/A N/A Ainos N/A N/A N/A Which has better earnings & valuation, HUMAW or AIMDW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHumacyte$2.02MN/AN/AN/AN/AAinos$18.11KN/AN/AN/AN/A SummaryHumacyte and Ainos tied by winning 1 of the 2 factors compared between the two stocks.How does Humacyte compare to Alvotech?Humacyte (NASDAQ:HUMAW) and Alvotech (NASDAQ:ALVOW) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings. Is HUMAW or ALVOW more profitable? Company Net Margins Return on Equity Return on Assets HumacyteN/A N/A N/A Alvotech N/A N/A N/A Which has stronger earnings and valuation, HUMAW or ALVOW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHumacyte$2.02MN/AN/AN/AN/AAlvotech$586.32MN/AN/AN/AN/A Does the media prefer HUMAW or ALVOW? In the previous week, Humacyte's average media sentiment score of 0.00 equaled Alvotech'saverage media sentiment score. Company Overall Sentiment Humacyte Neutral Alvotech Neutral SummaryAlvotech beats Humacyte on 1 of the 1 factors compared between the two stocks.How does Humacyte compare to Aravive?Humacyte (NASDAQ:HUMAW) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings. Does the media prefer HUMAW or ARAV? In the previous week, Humacyte's average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score. Company Overall Sentiment Humacyte Neutral Aravive Neutral Which has stronger earnings & valuation, HUMAW or ARAV? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHumacyte$2.02MN/AN/AN/AN/AAraviveN/AN/AN/A-$0.90N/A Is HUMAW or ARAV more profitable? Company Net Margins Return on Equity Return on Assets HumacyteN/A N/A N/A Aravive N/A N/A N/A Do insiders and institutionals have more ownership in HUMAW or ARAV? 35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryAravive beats Humacyte on 2 of the 3 factors compared between the two stocks.How does Humacyte compare to Atlantic Coastal Acquisition Corp. II?Humacyte (NASDAQ:HUMAW) and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) are both pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability. Which has higher valuation & earnings, HUMAW or ACABW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHumacyte$2.02MN/AN/AN/AN/AAtlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A Does the media prefer HUMAW or ACABW? In the previous week, Humacyte's average media sentiment score of 0.00 equaled Atlantic Coastal Acquisition Corp. II'saverage media sentiment score. Company Overall Sentiment Humacyte Neutral Atlantic Coastal Acquisition Corp. II Neutral Is HUMAW or ACABW more profitable? Company Net Margins Return on Equity Return on Assets HumacyteN/A N/A N/A Atlantic Coastal Acquisition Corp. II N/A N/A N/A SummaryHumacyte beats Atlantic Coastal Acquisition Corp. II on 1 of the 1 factors compared between the two stocks.How does Humacyte compare to Avidity Biosciences?Humacyte (NASDAQ:HUMAW) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment. Does the media favor HUMAW or RNA? In the previous week, Avidity Biosciences had 5 more articles in the media than Humacyte. MarketBeat recorded 5 mentions for Avidity Biosciences and 0 mentions for Humacyte. Avidity Biosciences' average media sentiment score of 0.80 beat Humacyte's score of 0.00 indicating that Avidity Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Humacyte Neutral Avidity Biosciences Positive Do analysts prefer HUMAW or RNA? Avidity Biosciences has a consensus target price of $69.42, indicating a potential upside of 436.07%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Avidity Biosciences is more favorable than Humacyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Humacyte 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Avidity Biosciences 1 Sell rating(s) 11 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.37 Which has higher valuation and earnings, HUMAW or RNA? Humacyte has higher earnings, but lower revenue than Avidity Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHumacyte$2.02MN/AN/AN/AN/AAvidity Biosciences$36.68M6.04-$322.30MN/AN/A Is HUMAW or RNA more profitable? Humacyte has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Humacyte's return on equity of 0.00% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets HumacyteN/A N/A N/A Avidity Biosciences -3,650.39%-44.92%-39.57% SummaryAvidity Biosciences beats Humacyte on 7 of the 10 factors compared between the two stocks. Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMAW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HUMAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HUMAW vs. The Competition ExportMetricHumacyteBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$465.73M$6.25B$12.23BDividend YieldN/A3.87%2.80%5.32%P/E RatioN/A3.7620.7925.05Price / SalesN/A7,435.94531.2172.69Price / CashN/A13.1343.0954.25Price / BookN/A83.539.816.83Net IncomeN/A-$96.07M$3.55B$335.69M7 Day PerformanceN/A0.22%-2.12%-2.15%1 Month PerformanceN/A0.83%-4.14%-2.47%1 Year PerformanceN/A69.66%28.34%27.13% Humacyte Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HUMAWHumacyteN/A$0.06-1.8%N/A-85.8%$0.00$2.02MN/A150Gap DownAIMDWAinosN/A$0.07+3.8%N/A-54.1%$0.00$18.11KN/A40News CoverageALVOWAlvotechN/A$0.24+20.0%N/A-89.2%$0.00$586.32MN/A4Gap UpARAVAraviveN/A$0.04flatN/AN/A$0.00N/AN/A20High Trading VolumeACABWAtlantic Coastal Acquisition Corp. IIN/A$0.00flatN/AN/A$0.00N/AN/A15 Related Companies and Tools Related Companies AIMDW Competitors ALVOW Competitors ARAV Competitors ACABW Competitors RNA Competitors BFRIW Competitors CELUW Competitors CINGW Competitors CMRAW Competitors DRMAW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HUMAW) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...Profits Run | SponsoredThe one number Musk can't hide in the S-1When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...Behind the Markets | SponsoredHe doesn't buy gold. He just profits from it.Former hedge fund manager Larry Benedict generated $274 million in profits - and Barron's ranked his fund in t...Brownstone Research | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
